<DOC>
	<DOCNO>NCT02842203</DOCNO>
	<brief_summary>This observational study evaluate circulate tumor DNA ( ctDNA ) prognostic marker monitor disease recurrence stage III colorectal cancer ( CRC ) .</brief_summary>
	<brief_title>Use ctDNA Monitoring Stage III Colorectal Cancer</brief_title>
	<detailed_description>Circulating tumor DNA ( ctDNA ) small fragment nucleic acid originate apoptotic necrotic tumor cell turnover . Characteristic malignant process , ctDNA assess plasma offer potential sensitive specific biomarker prognostic information disease-free overall survival , predictive information chemotherapy resistance probability lack response treatment . This study evaluate ctDNA prognostic marker monitor disease recurrence stage III colorectal cancer ( CRC ) . We recruit newly diagnose stage III CRC patient , determine tumor mutational profile , systematically collect high volume ( &gt; 10 ml ) , serial plasma specimen every 3 month 3 year every 6 month year 4-5 ctDNA concurrent carcinoembryonic antigen ( CEA ) measurement . Clinical outcome survival track . The result data permit assessment ctDNA prognostic marker disease-free overall survival monitor disease recurrence comparison CEA .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Men woman CRC Stage III A , B , C Age â‰¥18 year Willingness provide blood sample research purpose Ability understand write informed consent document , write informed consent provide Blood sample would compromise patient overall health presence severe anemia Unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>colorectal cancer</keyword>
</DOC>